PRESS RELEASE published on 07/18/2023 at 08:00, 1 year 4 months ago Defence Therapeutics Inc.: DEFENCE SUCCESSFULLY COMPLETES THE FIRST MILESTONE OF ITS COLLABORATION AGREEMENT WITH ORANO
PRESS RELEASE published on 07/04/2023 at 08:00, 1 year 4 months ago DEFENCE AND VIEWPOINT WITH DENNIS QUAID JOIN FORCES TO EXPLORE BREAKTHROUGHS IN BIOTECHNOLOGY
PRESS RELEASE published on 06/28/2023 at 17:21, 1 year 4 months ago Defence Therapeutics Inc.: DEFENCE PATENT PORTFOLIO AT THE FOREFRONT OF SUCCESS
PRESS RELEASE published on 06/20/2023 at 08:00, 1 year 5 months ago DEFENCE’S PROPRIETARY ACCUM(TM) TECHNOLOGY FOR DELIVERY OF CRISPR/CAS GENOME-EDITING COMPLEXES PATENT APPLICATON PUBLISHED
PRESS RELEASE published on 06/16/2023 at 08:00, 1 year 5 months ago DEFENCE MANUFACTURING OF ACCUTOXTM CGMP FINAL DRUG PRODUCT OPTIMIZATION FOR ITS PHASE I CLINICAL TRIAL AT CITY OF HOPE
PRESS RELEASE published on 06/06/2023 at 08:00, 1 year 5 months ago Defence Therapeutics Inc.: DEFENCE BEGINS TESTING ITS ARM VACCINE AGAINST PANCREATIC CANCER
PRESS RELEASE published on 05/24/2023 at 08:00, 1 year 5 months ago Defence Therapeutics Inc.: BREAKTHROUGH RESULTS: DEFENCE’S ARM VACCINE CURED 100% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA
PRESS RELEASE published on 05/02/2023 at 08:00, 1 year 6 months ago Defence Therapeutics Inc.: DEFENCE’S SUCCESFULL ACCUTOXTM PRE-CLINICAL EFFICACY STUDY COMPLETE READY FOR PHASE I IND FILING
PRESS RELEASE published on 04/27/2023 at 08:00, 1 year 6 months ago Defence Therapeutics Inc.: USPTO GRANTS TRADEMARK REGISTRATION FOR DEFENCE THERAPEUTICS®
PRESS RELEASE published on 04/24/2023 at 08:00, 1 year 6 months ago Defence Therapeutics Inc.: DEFENCE GRANTED US PATENT WITH BROAD COVERAGE ON ACCUMTM-BASED VACCINE ENHANCER PLATFORM TECHNOLOGY
Published on 11/22/2024 at 00:00, 6 hours 27 minutes ago Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 8 hours 22 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 8 hours 37 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 10 hours 12 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 10 hours 17 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 19:01, 11 hours 26 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 11 hours 51 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 12 hours 28 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 12 hours 35 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 12 hours 35 minutes ago 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 06:58, 23 hours 29 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 11 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 12 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 12 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 22 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
